Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction. (1st October 2018)

• Record Type: Journal Article
• Authors: Orrem, Hilde L.; Shetelig, Christian; Ueland, Thor; Limalanathan, Shanmuganathan; Nilsson, Per H.; Husebye, Trygve; Aukrust, Pål; Seljeflot, Ingebjørg; Hoffmann, Pavel; Eritsland, Jan; Mollnes, Tom E.; Andersen, Geir Øystein; Yndestad, Arne
• Is Part Of: International journal of cardiology. Volume 268(2018)
• Page Start: 187
• Page End: 192
• Publication Date: 2018-10-01
• Subjects: Inflammation -- Cytokine -- Interleukin-1 -- Acute coronary syndromes -- Myocardial infarction -- Ventricular remodelling; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2018.05.032
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: The inflammatory response following myocardial infarction (MI) is prerequisite for proper healing of infarcted tissue, but can also have detrimental effects on cardiac function. Interleukin (IL)-1α and IL-1β are potent inflammatory mediators and their bioactivity is tightly regulated by IL-1 receptor antagonist (IL-1ra) and soluble (s) IL-1 receptors (R). We aimed to examine whether levels of soluble regulators of IL-1 signalling are changed during ST-elevation MI (STEMI) and their associations with parameters of cardiac injury and ventricular remodelling. Methods: Plasma levels of IL-1Ra, sIL-1R1, sIL-1R2 and sIL-1R accessory protein (sIL-1RAcP) were measured by immunoassays in repeated samples from patients with STEMI ( n = 255) and compared to healthy controls ( n = 65). Results: IL-1Ra, sIL-1R1 and sIL-1R2 levels were all significantly elevated after STEMI, while levels of sIL-1RAcP were lower compared to controls. sIL-1R2 levels (at different time points) correlated positively with C-reactive protein, myocardial infarct size and change in indexed left ventricular end-diastolic and end-systolic volume (LVEDVi and LVESVi) measured by cardiac MR acutely and after 4 months, and negatively with LV ejection fraction. Patients with >median levels of sIL-1R2 in the acute phase were more likely to have increased change in LVEDVi and LVESVi. Importantly, sIL-1R2 remained significantly associated with change in LVEDVi and LVESVi also after adjustment for clinical covariates. Conclusion: Levels of sIL-1R2 are independently associated with parameters of LV adverse remodelling following STEMI. Highlights: IL-1 bioactivity is regulated at several levels including by soluble receptors. Levels of soluble regulators of IL-1 activity are changed in patients with STEMI. Soluble IL-1 receptor 2 (sIL-1R2) remain elevated in the acute and chronic phase. Levels of sIL-1R2 are strongly associated with development of LV remodelling. sIL-1R2 levels associate with remodelling after adjustment for clinical covariates.